We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Assay Determines Suitability of Nanoparticles for In Vivo Use

By LabMedica International staff writers
Posted on 28 Feb 2017
A team of Swiss researchers has developed a flow cytometry-based test to determine whether specific types of nanoparticles are suitable for use in humans or animals.

Nanoparticles as carriers of drugs, genetic material, or other substances of biomedical interest are under investigation in many laboratories. However, their interaction with immune cells has been difficult to predict. Macrophages are among the first type of cells that take up nanoparticles, mediating inflammation and thus immunological responses. A recent study described a highly reproducible screening method to study the interaction of nanoparticles with macrophages.

Image: Macrophages with ingested nanoparticles (green) (Photo courtesy of the Bourquin Laboratory, University of Geneva).
Image: Macrophages with ingested nanoparticles (green) (Photo courtesy of the Bourquin Laboratory, University of Geneva).

Investigators at the University of Geneva and the University of Fribourg reported in the February 2, 2017, online edition of the journal Nanoscale that they had developed a flow cytometry-based assay that could determine for a single nanoparticle sample whether the nanoparticles were taken up by macrophages, whether the nanoparticles caused death of the macrophages, and whether the nanoparticles triggered an inflammatory immune response.

To perform the assay, macrophages were brought into contact with the nanoparticles for 24 hours, and were then evaluated in a flow cytometer. The fluorescence emitted by the macrophages made it possible to count them and characterize their activation levels. Since the particles themselves were fluorescent, the investigators could also measure the amount of particles ingested by the macrophages. Thus, the three elements could be determined simultaneously in two or three days on a very small amount of particles.

"Researchers can spend years developing a nanoparticle, without knowing what impact it will have on a living organism," said senior author Dr. Carole Bourquin, professor of medicine at the University of Geneva. "So there was a real need to design an effective screening method that could be implemented at the beginning of the development process. Indeed, if the nanoparticles aren’t compatible, several years of research were simply thrown away."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Gold Member
Platelet Function Analyzer
PL-12

Latest BioResearch News

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
28 Feb 2017  |   BioResearch

New Immune Target Could Support More Precise High Blood Pressure Treatment
28 Feb 2017  |   BioResearch

New Gene-Disease Link May Help Diagnose Rare Neurodevelopmental Disorders
28 Feb 2017  |   BioResearch